IMG_20220629_101126

Brief Profile

From applied therapeutics, trying to arrest visceral leishmaniasis during her PhD, to working on malaria vaccination during her post-doctoral studies, Debabani has always been pushed by the urge to find better treatments for diseases. In her new role at Mestastop, she is looking into the modalities of EM hybrids.

Dr. Debabani Roy Chowdhury

Cellular Immunology & Cell Biology

Designation:Director
Location:Bangalore

Qualification

 PhD with 12+ years of experience
 Bloomberg School of Public Health, Johns Hopkins
 CCMB, DST WoS-A grant awardee,
 15 Publications

Awards & Certifications

 Multiple Best Poster Awards, CSIR – NET
 Order of Merit in BS & MS from Calcutta University

Mumbai Angels

Pudnaa

Developer

“Mestastop is charting a pioneering and much-needed path to early detection of metastasis. Such work is key to furthering mankind’s understanding of human health”

Dr. D.C Doval

Krishnan D

Developer

“If Mestastop can predict metastasis probability of primary cancer patients, that will be a game changer for doctors”

Dr. A. K Vaid

Doctor

Developer

“Mestastop provides a great opportunity at finding solutions to the unmet medical needs in cancer care”

Dr. A. Kamath

Pudnaa

Developer

“Concept-wise, it is a much-needed approach to address metastasis; looks very interesting and perhaps doable with Arnab’s keen interest and passion”

CIIE

Clifi sinto

Developer

“Mestastop platform will play an instrumental role in changing cancer treatment in India and the world around”